Murizatoclax

N/A

Report date: 2024/02/05 16:46:46
NME

Base Information

Drug NameMurizatoclax
Drug Alias NameAMG-397
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInduced myeloid leukemia cell differentiation protein Mcl-1 inhibitors
TargetsInduced myeloid leukemia cell differentiation protein Mcl-1
Therapy Area/IndicationsMyelodysplastic SyndromesMultiple MyelomaLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyAustralia +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeOne Medicines LtdAmgen Inc
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesMultiple MyelomaLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank